Tango Therapeutics Q3 2023 Earnings Report

Tango Therapeutics EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$0.34
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

Tango Therapeutics Revenue Results

• Actual Revenue: $10.73 million
• Expected Revenue: $8.05 million
• Beat/Miss: Beat by +$2.68 million
• YoY Revenue Growth: N/A

Tango Therapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/8/2023
• Time: N/A

Tango Therapeutics (NASDAQ:TNGX), a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.